Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 15, 2001

View Archived Issues

Serono confirms submission of Rebif amendment to FDA

Bausch & Lomb acquires loteprednol etabonate line

FDA issues approvable letter for UroXatral

CAT and Merck & Co. form HIV alliance

Maxygen brings two new therapeutics into preclinical pipeline

Roche's PEGASYS introduced in first market

Inhibition of p38 MAPK in experimental model of colitis has dual effect

Efficacy of MAP kinase blocker CNI-1493 in Crohn's disease seen in pilot trial

Gene therapy with IL-10 produces therapeutic benefit in experimental colitis

Matrix to initiate new study of tezacitabine in AML

High-dose ISIS-2302 enemas improve symptoms in ulcerative colitis

Favorable OvaRex/chemotherapy clinical trial results in relapsed ovarian cancer reported by AltaRex

First clinical data for new propofol prodrug presented at ASA meeting

GlycoDesign and Leo move new antithrombotics into clinical trials

Cardioprotective effects of landiolol and propranolol compared in guinea pig hearts

MGI Pharma expands phase II irofulven clinical trial in ovarian cancer

Potential new therapeutic target for endotoxin shock: anandamide

Cardioprotective and vasodilating effects described for JTV-519 at ASA meeting

Peregrine's Cotara receives FDA fast track review status

FDA issues approvable letter for Symlin in type 1 and type 2 diabetes

New clinical data show Multikine's ability to eliminate HPV-induced cervical dysplasia

Neuroprotective aminoadamantane derivatives disclosed by Panorama

New VLA-4 antagonists in the Kaken pipeline

Selective dopamine D3 receptor antagonists identified by Pharmacia

Two Japanese patents cover Otsuka's new hypoglycemic/hypolipidemic compounds

Inhibitors of CDKs useful as anticancer agents

Antitumor antibiotics discovered at MCRF in Streptomyces

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...